Nasal Swine Flu Vaccine. MedImmune, a unit of AstraZeneca, has become the third company in the last couple of months to issue a recall of a swine flu vaccine. In November, GlaxoSmithKline recalled 100,000 doses of its swine flu vaccine in Canada Public Health Agency of Canada has received a higher than expected number of reports of anaphylaxis in this lot number compared to other lots.
Just last week, Sanofi Pasteur recalled 800,000 doses of a swine flu vaccine meant for infants because of potency issues. At the time of the recall, health regulators said children who have received vaccine from the recalled lots will not need to be re-vaccinated because potency is only slightly below the “specified” range.
According to MedImmune’s recall notice, its swine flu vaccine is also being recalled over potency concerns.
The recall involves 13 lots of the company’s nasal spray monovalent H1N1 flu vaccine
The recall involves 13 lots of the company’s nasal spray monovalent H1N1 flu vaccine distributed throughout the U.S. The lot numbers involved in this recall are:
Most of the recalled swine flu vaccine was given out in October and November, and would have been fully potent then. About 300,000 doses are left in warehouses. MedImmune is recalling the unused doses.
People who received a swine flu vaccine from one of these lots do not need to be revaccinated, MedImmune said. The vaccine potency is only slightly below what it is supposed to be.
The vaccine in these lots is still expected to be effective in stimulating a protective response.